A major challenge in understanding SARS-CoV-2 evolution is interpreting the antigenic and
functional effects of emerging mutations in the viral spike protein. Here, we describe a deep …

The emergence of SARS-CoV-2 has seriously affected the lives of people worldwide.
Clarifying the attenuation rule of SARS-CoV-2 neutralizing antibody (NAb) in vivo is the key …

During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic,
multiple variants escaping preexisting immunity emerged, causing reinfections of previously …

SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …

Viral diseases represent a major public health concerns and ever-present risks for
developing into future pandemics. Antiviral antibody therapeutics, either alone or in …

The antiviral benefit of antibodies can be compromised by viral escape especially for rapidly
evolving viruses. Therefore, durable, effective antibodies must be both broad and potent to …

The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires
ongoing monitoring to judge the ability of newly arising variants to escape the immune …

SARS-CoV-2 variants acquire mutations in spike that promote immune evasion and impact
other properties that contribute to viral fitness such as ACE2 receptor binding and cell entry …

The SARS-CoV-2 spike glycoprotein has 22 potential N-linked glycosylation sites per
monomer that are highly conserved among diverse variants, but how individual glycans …

SUMMARY SARS-CoV-2 continues to evolve and evade most existing neutralizing
antibodies, including all clinically authorized antibodies. We have isolated and …